You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Efficacy

Greater improvement in lung function vs. tiotropium 1

Once-daily Incruse provided a significantly greater trough FEV1 improvement of 59 mL from baseline vs. tiotropium HandiHaler® (154 mL vs. 95 mL; p<0.001) at Day 85 1

Change from baseline in trough FEV1 at Day 85 1

 

Adapted from Feldman et al. 2016 1

FEV1, forced expiratory volume in 1 second.

  • Study design

    Data from a 12-week, randomised, blinded, double-dummy, parallel-group study. Patients were required to have a mean predicted FEV1 of ≥30% and ≤70% at baseline. Least squares (LS) mean change from baseline at Day 85 was 154 mL for Incruse and 95 mL for tiotropium HandiHaler®. 1 Primary endpoint: trough FEV1 on Day 85. Data are for the per-protocol population. 1 Details of the blinding process for the tiotropium comparator study discussed here can be found on page 1 of Supplementary Material, Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016; 11:719–730.

Improved efficacy from baseline vs. tiotropium 1

Once-daily Incruse significantly improved 12–24h weighted mean FEV1 vs. tiotropium HandiHaler® (145 mL vs. 138 mL; p=0.015) 1

Change from baseline in serial FEV1 over 0–24h post-dose on Day 84 1

Adapted from Feldman et al. 2016 1

FEV1, forced expiratory volume in 1 second.

  • Study design

    Data from a 12-week, randomised, double-blind, double-dummy, parallel-group study. Patients were required to have a mean predicted FEV1 of ≥30% and ≤70% at baseline. Weighted mean FEV1 12–24h was a secondary endpoint. Data are for the 24-hour population (all patients in the intent-to-treat population for whom 24-hour spirometry was performed). 1 Details of the blinding process for the tiotropium comparator study discussed here can be found on page 1 of Supplementary Material, Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016; 11:719–730.

Non-inferiority vs. the LAMA glycopyrronium 2

Once-daily Incruse showed non-inferiority compared with glycopyrronium Breezhaler® (trough FEV1 at Day 85 treatment difference: 24 mL, 95% CI: -5–54) 2

Change from baseline in trough FEV1 2

Adapted from Rheault et al. 2016 2

CI, confidence interval; FEV1, forced expiratory volume in 1 second.

  • Study design

    Data from a 12-week, multicentre, randomised, open-label, parallel-group study. Patients were required to have a mean predicted FEV1 of ≥30% and ≤70% at baseline. Least squares (LS) mean change from baseline at Day 85 was 123mL for Incruse and 99mL for glycopyrronium Breezhaler®. 2 Primary endpoint: trough FEV1 on Day 85. Data are for the per-protocol population.

Improved health-related quality of life vs. placebo 4

Treatment with Incruse Ellipta resulted in clinically meaningful improvement of 4.7 units in SGRQ total score vs. placebo on Day 168 (-7.25 vs. -2.56; p<0.001) 4

Change from baseline in SGRQ total score on Day 168 4

Adapted from Donohue et al. 2013

SGRQ, St George’s Respiratory Questionnaire.

  • Study design

    Data from a 24-week, randomised, double-blind, double-dummy, parallel-group study. Patients were required to have a mean predicted FEV1 of ≥30% and ≤70% at baseline. Primary endpoint: trough FEV1 on Day 169. SGRQ score was a secondary endpoint. 4 A step-down statistical procedure was used in this study and this outcome was below an endpoint that did not achieve statistical significance; therefore statistical significance on this comparison cannot be inferred.

Improved COPD symptoms vs. placebo 4

Incruse Ellipta demonstrated clinically meaningful improvement of 1.0 unit in TDI focal score vs. placebo on Day 168 (2.2 vs. 1.2 units; p≤0.001) 4

Change from baseline in TDI focal score on Day 168 4

Adapted from Donohue et al. 2013 4

TDI, Transition Dyspnoea Index

  • Study design

    Data from a 24-week, randomised, double-blind, double-dummy, parallel-group study. Patients were required to have a mean predicted FEV1 of ≥30% and ≤70% at baseline. Primary endpoint: trough FEV1 on Day 169. TDI focal score was a secondary endpoint. 4

Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health http://www.phs.moh.gov.cy/web/guest/drug-search

References:

  1. Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016; 11:719–730 (supplementary material).
  2. Rheault T et al. ERJ Open Res 2016;2: pii:00101-2015.
  3. Ismaila AS et al. Int J Chron Obstruct Pulmon Dis 2015; 10:2495–2517.
  4. Donohue JF et al. Respir Med 2013; 107:1538–1546.

Trade marks are owned by or licensed to the GSK group of companies.
© 2018 GSK group of companies or its licensor.